Review: Telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1

Annals of Internal Medicine

Volumn 161, Issue 10, 2014, Pages JC11-

  Kottilil, S ^a   Koretz, Ronald L ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DRUG SAFETY; END STAGE LIVER DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CELL CARCINOMA; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; HEPACIVIRUS; HEPATITIS C, CHRONIC; PHYSIOLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 84923286503     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-161-10-201411180-02011     Document Type: Note

References (4)

1. Wiese M, Fischer J, Lobermann M, et al; East German HCV Study Group. Hepatology. 2014;59: 49-57.
2. Hara K, Rivera MM, Koh C, et al. J Infect Dis. 2014;209: 38-45.
3. Van der meer AJ, Feld JJ, Hofer H, et al. Hepatology. 2013;58(Suppl4): 280A.
4. Koretz RL, Pleguezuelo M, Arvaniti V, et al. Cochrane Database Syst Rev. 2013;1: CD003617.